AI Article Synopsis

  • Paragangliomas (PGL) are uncommon neuroendocrine tumors that arise from chromaffin cells in the autonomic nervous system, and this study focuses on their long-term outcomes based on a decade of patient data.
  • The research involved a retrospective analysis of 46 patients diagnosed with abdominal PGL, revealing an average diagnosis age of 55.4 years and a typical tumor size of 5.85 cm, with most tumors located below the kidneys.
  • Although abdominal PGL has a favorable long-term prognosis, cases of recurrence can happen well after the initial diagnosis, particularly in patients with a higher Pheochromocytoma of the Adrenal Gland Scaled Score (PASS), thus emphasizing the need for

Article Abstract

Purpose: Paragangliomas (PGL) are rare neuroendocrine tumors derived from chromaffin cells of the autonomic nervous system. We aim to describe our experience and the long-term outcome of abdominal PGL over the last decade.

Methods: A retrospective review of patients diagnosed with PGL in our hospital between November 2005 and June 2017 was conducted. All nonabdominal PGL were excluded and the clinicopathological features and long-term outcomes of the patients were analyzed.

Results: A total of 46 patients were diagnosed with abdominal PGL. The average age of diagnosis was 55.4 years and there was no sex predilection. The average tumor size was 5.85 cm and they were predominantly located in the infrarenal position (50%). The mean follow-up period was 42 months (range, 1.8-252 months). All patients with metastases had Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) of ≥4. One patient presented with synchronous metastases while 2 developed local recurrence and distant metastases. One presented with only local recurrence. One patient died 5 years after diagnosis.

Conclusion: Abdominal PGL is a rare tumor with excellent long-term prognosis. Recurrence although uncommon, can occur decades after initial diagnosis. Long-term follow-up is therefore recommended for all patients with PGL, especially in patients with PASS of ≥4.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704273PMC
http://dx.doi.org/10.4174/astr.2020.99.6.315DOI Listing

Publication Analysis

Top Keywords

abdominal pgl
12
long-term outcomes
8
pgl rare
8
patients diagnosed
8
pass ≥4
8
local recurrence
8
pgl
7
patients
6
long-term
5
abdominal
4

Similar Publications

Durable and deep response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report.

Front Endocrinol (Lausanne)

January 2025

Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Introduction: Succinate dehydrogenase subunit B (SDHB)-mutated paragangliomas (PGLs) are rare neuroendocrine tumors characterized by increased malignancy, readily metastasizing, and poorer prognosis. Here we report a case of SDHB-mutated metastatic PGL, wherein the patient showed significant tumor shrinkage and complete symptom remission following chemotherapy. We aim to contribute additional evidence to the existing knowledge associated with SDHB-mutated PGLs.

View Article and Find Full Text PDF

Background: Dachaihu decoction (Dachaihu tang) plays a crucial role in treating acute illnesses. Recently, a significant number of clinical studies on Dachaihu decoction for acute cholecystitis (AC) have been published. This study was conducted to assess the efficacy and safety of Dachaihu decoction in patients with this condition.

View Article and Find Full Text PDF

Mesenteric paragangliomas (PGLs) are extremely rare, with a limited number of reported cases. These tumors are typically non-functioning and commonly manifest as a palpable abdominal mass or abdominal pain; however, a significant proportion of patients remain asymptomatic. Despite their rarity, they should be considered in the differential diagnosis of mesenteric masses.

View Article and Find Full Text PDF

Genotype and clinical phenotype characteristics of germline mutation-associated pheochromocytoma/paraganglioma syndrome.

Front Endocrinol (Lausanne)

September 2024

Laboratory Department of Oncologic and Urologic Surgery, The 903rd PLA Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Article Synopsis
  • * A total of 109 patients from 87 families were analyzed, revealing common mutations like p.R33*, p.R75*, and p.A67D, which together constituted over 42% of the mutations identified.
  • * The findings suggest that germline mutations could lead to new forms of multiple endocrine neoplasia, highlighting the importance of thorough assessment for individuals with these mutations, especially considering the risk of developing bilateral PCCs and metastases.
View Article and Find Full Text PDF
Article Synopsis
  • * The patient experienced skin rashes and elevated glucagon levels throughout treatment but underwent several surgeries, including pancreatic and liver tumor resections, which led to initial improvements in skin symptoms and glucagon levels post-surgery.
  • * By April 2024, although there were no significant skin symptoms, there was noted progression of liver lesions, indicating that the disease was still advancing despite surgical intervention.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!